Microsoft: Earnings Estimates For Q1 2022

Microsoft (NASDAQ: MSFT) will be reporting its first quarter financial results on the 26th after the markets close. Analysts have a consensus $339.26 12-month price target on the company, via a total of 41 analysts, with 17 analysts having strong buy ratings. 22 analysts meanwhile have buy ratings, and 2 analysts have hold ratings on the company. The street high sits at a $384 price target, and the lowest target sits at $281.78.

25 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 25 analysts is $44.97 billion; this number has been revised upwards from $41.90 billion at the start of April. The highest revenue estimate is $44.77 billion, while the lowest is $43.66 billion.

Onto EBITDA estimates, there are currently 4 analysts who have first-quarter EBITDA estimates. The mean is currently $22.28 billion, with this number having been revised upwards from $20.35 billion at the start of April. The street high estimate currently sits at $22.76 billion in EBITDA and the lowest is $21.56 billion.

Analysts estimate that quarterly earnings per share will come in at $2.07, with this number being revised upwards from $1.90 at the start of April. Street high is $2.17 and the lowest estimate is $2.03 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Power Metallic Pushes Deeper Into Saudi Arabia With Amaar Mining Tie-Up

Canada Confirms First Hantavirus Case Linked to MV Hondius Cruise Ship Outbreak

Related News

Teladoc Health: Numerous Analysts Raise Price Targets Following Q3 Earnings

Yesterday, Teladoc Health (NYSE: TDOC) reported its third quarter earnings results, reporting $228.8 million in...

Saturday, October 31, 2020, 02:02:00 PM

BMO Lowers Price Target On Equinox Gold Following Production Suspension At RDM Mine

Earlier this month Equinox Gold (TSX: EQX) revealed that they are temporarily suspending operations at...

Monday, May 30, 2022, 10:58:00 AM

Dollarama: BMO Labels Firm As Best Inflation Stock Pick, Lifts Target To $95

On August 24, BMO Capital Markets raised their 12-month price target on Dollarama (TSX: DOL)...

Saturday, August 27, 2022, 05:05:00 PM

Curaleaf: The Analyst Take On The European Expansion

On April 7th, Curaleaf Holdings (CSE: CURA) announced that they completed $312 million acquisition of...

Friday, April 9, 2021, 11:46:00 AM

Canopy Growth: Canaccord Reduces Target To $6, Anticipates Further Cost Cutting

Canopy Growth (TSX: WEED) is expected to report its fiscal fourth-quarter financial results tomorrow morning....

Thursday, May 26, 2022, 04:32:00 PM